{
  "title": "Paper_535",
  "abstract": "pmc Nanoscale Adv Nanoscale Adv 4221 nanoadv NA Nanoscale Advances 2516-0230 Royal Society of Chemistry PMC12481217 PMC12481217.1 12481217 12481217 41036418 10.1039/d5na00555h d5na00555h 1 Chemistry Engineered riboflavin–cerium oxide nanoparticles for enhanced phototoxicity toward triple-negative breast cancer cells https://orcid.org/0009-0002-3601-6955 Wongpan Anongnat a Nuchpun Sopon a Tana-atsawapon Napasorn a https://orcid.org/0000-0001-8658-0234 Luksirikul Patraporn b c https://orcid.org/0000-0003-4873-6378 ACP-0452-2022 Suriyarak Sarisa d Artsanthia Jintana e https://orcid.org/0000-0001-6417-4921 J-7741-2017 Katewongsa Kanlaya Prapainop a  a Department of Biochemistry, Faculty of Science, Mahidol University Bangkok 10400 Thailand anongnat.won@gmail.com nuchpun.s@gmail.com napasorn.taa@student.mahidol.edu kanlaya.pra@mahidol.ac.th  b Department of Chemistry, Faculty of Science, Kasetsart University Bangkok 10900 Thailand fscipplu@ku.ac.th  c Center for Advanced Studies in Nanotechnology for Chemical, Food and Agricultural Industries, KU Institute for Advanced Studies, Kasetsart University Bangkok 10900 Thailand  d Department of Food Technology, Faculty of Science, Chulalongkorn University Bangkok 10330 Thailand sarisa.s@chula.ac.th  e Department of Community Nursing, Faculty of Nursing, Saint Louis College Bangkok 10120 Thailand jintana.a@slc.ac.th 10 9 2025 475012 5 6 2025 9 9 2025 10 09 2025 01 10 2025 02 10 2025 This journal is © The Royal Society of Chemistry 2025 RSC https://creativecommons.org/licenses/by-nc/3.0/ This article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence Cerium oxide nanoparticles (CeO 2 2 In vitro 2 2 2 Rf–CeO 2 Mahidol University 10.13039/501100004156 FF-079/2567 Kasetsart University Research and Development Institute 10.13039/501100005621 FF(KU)23.67 pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf yes pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pubstatus Advance Article 1. Introduction Breast cancer is a major global health burden. It is a highly heterogeneous malignancy that presents with multiple subtypes, each with distinct molecular and epidemiological characteristics. 1 2–5 6 Nanotechnology offers new platforms for administering cancer treatment, such as drug delivery, molecular targeting, and therapeutic activation. 7 2 8–10 3+ 4+ 11 12,13 14 15,16 Nanoceria has stood out as a promising therapeutic agent in breast cancer because of its ability to modulate intracellular ROS, which is crucial in tumor progression, therapeutic resistance, and treatment responsiveness. 17 2 18–20 21–24 25,26 2 2 via Recent studies have demonstrated that Rf-conjugated nanocarriers improved cellular delivery in breast cancer cells 27–30 31 2 2 2. Experimental section 2.1 Materials Cerium( iii 3 3 2 N N N 2 4 2 4 2.2 Methods 2.2.1 Synthesis of CeO 2 To synthesize CeO 2 3 3 2 g 2 2.2.2 Synthesis of amine-functionalized CeO 2 Amine-functionalized CeO 2 2 2 32 2 g g 2 2 2.2.3 Synthesis of Rf–CeO 2 Rf molecules were functionalized onto NH 2 2 2 2 Fig. 1 2 2 g 2 2 2 2 2 2 2 Fig. 1 Schematic illustration of the synthesis and riboflavin (Rf) functionalization of cerium oxide nanoparticles (CeO 2 2 via 3 3 2 2 2 2 2 2 N 2 2 2.2.4 Characterization of the synthesized NPs 2.2.4.1 Dynamic light scattering measurement The hydrodynamic diameter and zeta potential of the synthesized NPs were analyzed by dynamic light scattering (DLS). Both measurements were performed with a Zetasizer Ultra (Malvern Panalytical) at a controlled temperature of 25 °C to ensure consistency. To optimize the measurement accuracy and minimize interference, the NP samples were diluted with deionized water as the dispersion medium at a 1 : 100 ratio for a final NP concentration of 0.1 mg mL −1 2.2.4.2 Transmission electron microscopy analysis The morphological characteristics and structural integrity of the NPs were visualized by transmission electron microscopy (TEM) with a JEM-3100 (HR) instrument. Prior to imaging, the NPs were redispersed in ethanol at a concentration of 0.5 mg mL −1 2.2.4.3 Field emission scanning electron microscopy analysis The morphology and size of the synthesized NPs were determined using a field emission scanning electron microscope (FESEM, FEI Quanta 450). The samples were prepared by placing the NPs on a carbon-coated copper grid, and the NPs were then gold-coated to improve the conductivity. 2.2.4.4 Fourier transform infrared spectroscopy analysis The Fourier-transform infrared (FTIR) spectra of the synthesized CeO 2 −1 −1 2 2.2.4.5 Powder X-ray diffraction The crystalline structure of the synthesized CeO 2 θ 2.2.5 Cell culture The TNBC cell line MDA-MB-231 (HTB-26) and normal breast epithelial cells MCF-10A were obtained from ATCC. MDA-MB-231 cells were cultured in DMEM with 10% FBS and 1% penicillin–streptomycin, while MCF-10A cells were maintained in DMEM/F12 with horse serum and insulin (Gibco, UK). EGF and hydrocortisone were from Sigma-Aldrich and HiMedia (Mumbai, India), respectively. Cells were incubated at 37 °C in 5% CO 2 2.2.6 Cell viability and photodynamic therapy assays The cytotoxicity of the NPs was evaluated using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2 H 3 2 2 2 −1 −1 −2 −1 All experiments were conducted in triplicate with at least three independent repeats to ensure reproducibility. 2.2.7 Intracellular ROS generation Intracellular ROS levels were quantified using the DCFDA/H2DCFDA Cellular ROS Assay Kit (Abcam, ab113851) following the manufacturer's protocol. MDA-MB-231 cells were seeded into black 96-well plates at a density of 2.5 × 10 4 2 2 2 −1 2.2.8 Mitochondrial membrane potential assay Mitochondrial membrane potential (MMP) was measured using the JC-1 assay (Dojindo Laboratories, Japan) according to the manufacturer's protocol. MDA-MB-231 cells were seeded in 96-well black, clear-bottom plates at a density of 2.5 × 10 4 2 2 2 −1 −2 3. Results 3.1 Characterization of CeO 2 2 CeO 2 2 Fig. 2a and d Fig. 2b and e 2 Fig. 2b Fig. 2e 2 2 Fig. 2c and f 2 2 2 2 2 2 2 2 2 Table 1 2 2 2 2 2 2 2 2 Fig. 2 Characterization of CeO 2 2 2 2 2 2 2 2 Table 1  D H 2 2 a Nanoparticles  D H PDI Zeta potential (mV) CeO 2 436.7 ± 92.91 0.48 ± 0.07 −22.3 Rf–CeO 2 363.7 ± 15.21 0.50 ± 0.03 28.6 a Hydrodynamic diameter ( D H 3.2 Fluorescence, FTIR, and XRD analyses of CeO 2 2 To functionalize Rf onto CeO 2 2 Fig. 3a 2 Fig. 3b 33 2 2 2 2 Fig. 3c 2 −1 −1 34 −1 −1 −1 <svg xmlns=\"http://www.w3.org/2000/svg\" version=\"1.0\" width=\"13.200000pt\" height=\"16.000000pt\" viewBox=\"0 0 13.200000 16.000000\" preserveAspectRatio=\"xMidYMid meet\"><metadata>\nCreated by potrace 1.16, written by Peter Selinger 2001-2019\n</metadata><g transform=\"translate(1.000000,15.000000) scale(0.017500,-0.017500)\" fill=\"currentColor\" stroke=\"none\"><path d=\"M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z\"/></g></svg> −1 −1 2 −1 −1 35 2 Fig. 3 Fluorescence, Fourier-transform infrared (FTIR) spectroscopy, and X-ray diffraction (XRD). (a) Structures of riboflavin (Rf) and Rf–citrate ester (CARf); (b) fluorescence intensity of CARf (red), Rf–CeO 2 2 2 2 Furthermore, the frequency bands at 850 and 540 cm −1 2 2 2 2 2 2 2 2 Fig. 3d θ 2 2 2 2 2 3.3 Cytotoxicity of CeO 2 2 The cytotoxicity of CeO 2 2 50 2 −1 2 50 −1 Fig. 4a 2 2 Fig. 4b 2 2 50 2 2 2 2 Fig. 4 The anti-cancer effect of CeO 2 2 n p p 3.4 Cytotoxicity of UV-irradiated CeO 2 2 To evaluate the effects of UV-activated CeO 2 2 2 2 Fig. 5a 2 50 −1 2 50 −1 50 2 2 50 −1 50 2 Fig. 5b 2 2 2 2 2 2 2 2 50 2 −1 50 50 −1 2 2 Fig. 5 Cytotoxic effects of UV-activated CeO 2 2 2 2 50 50 2 2 n p p p 3.5 Intracellular ROS generation assessed using the DCFDA fluorescence assay Based on the well-established redox mechanism of cerium oxide nanoparticles (CeO 2 3+ 4+ 2 2 2 2 −1 2 2 2 2 2 2 2 2 −1 Fig. 6a 2 Fig. 6b 2 2 2 2 2 2 2 2 2 2 2 −1 2 2 Fig. 6c 2 2 −1 2 2 2 2 Fig. 6 Measurement of intracellular reactive oxygen species (ROS) levels using the DCFDA fluorescence assay. (a) Cells were treated with either CeO 2 2 −1 2 2 −1 n p p p 3.6 MMP disruption assessed by JC-1 staining The enhanced cytotoxicity observed in Rf–CeO 2 2 2 −1 In the non-UV-treated groups, CeO 2 2 Fig. 7a 2 −1 2 2 −1 Fig. 7b Fig. 7 The assessment of mitochondrial membrane potential in MDA-MB-231 cells using JC-1 dye after treatment with CeO 2 2 −1 n p p However, Rf–CeO 2 2 −1 2 2 2 2 Fig. 7c 2 −1 2 2 To investigate whether the UV activation of Rf–CeO 2 2 2 2 2 2 4. Discussion TNBC presents a significant therapeutic challenge stemming from its aggressive nature and lack of specific molecular targets. Recent studies have investigated redox-modulating nanotherapeutics that are capable of exploiting the higher oxidative stress vulnerability of TNBC cells. 36,37 2 3+ 4+ 38–40 2 2 2 50 2 2 41,42 43,44 2 2 2 2 2 2 45 Importantly, our findings also establish that Rf functionalization improves the cellular uptake and tumor selectivity of CeO 2 46 47,48 2 2 The combination of active targeting via 2 2 2 2 2 2 2 2 in vivo 5. Conclusion This study demonstrated that Rf–CeO 2 2 2 2 2 2 Author contributions Anongnat Wongpan: conceptualization, methodology, visualization, investigation, formal analysis, writing – original draft, writing – review & editing. Sopon Nuchpun: methodology, visualization, investigation, writing – original draft. Napasorn Tana-atsawapon: methodology, investigation, writing – original draft. Patraporn Luksirikul: supervision, methodology, funding acquisition, writing – review & editing, resources. Sarisa Suriyarak: supervision, methodology, funding acquisition, writing – review & editing. Jintana Artsanthia: supervision, methodology, funding acquisition, writing – review & editing. Kanlaya Prapainop Katewongsa: supervision, conceptualization, methodology, funding acquisition, writing – review & editing, resources, project administration. Conflicts of interest There are no conflicts to declare. Supplementary Material NA-OLF-D5NA00555H-s001 Authors thank Assoc. Prof. Ekasith Somsook for the use of the instrument. This research project was funded by Mahidol University (Fundamental Fund: Fiscal Year 2024 by the National Science Research and Innovation Fund [NSRF] [FF-079/2567]). Partial support was also provided by a grant from the Center for Scientific Instrumentation and Platform Services, Faculty of Science, Mahidol University. A. W. was supported by a postdoctoral fellowship award from Mahidol University. S. N. was supported by the Development and Promotion of Science and Technology Talents Project. P. L. would like to thank the Kasetsart University Research Development Institute (KURDI) FF(KU)23.67, Kasetsart University and the departments at the Center for Advanced Studies in Nanotechnology for Chemical, Food, and Agricultural Industries, Kasetsart University Institute for Advanced Studies, Kasetsart University. Data availability The data supporting this article have been included as part of the SI. Supplementary information: dynamic light scattering (DLS) analysis, anti-cancer effect of Rf–CeO 2 2 https://doi.org/10.1039/d5na00555h Notes and references Loibl S. Poortmans P. Morrow M. Denkert C. Curigliano G. Breast cancer Lancet 2021 397 1750 1769 10.1016/s0140-6736(20)32381-3 33812473 Lee S.-K.  et al. Nano Lett. 2012 12 2697 2704 10.1021/nl2041707 22646476 PMC3381426 Dicheva B. M.  et al. Nano Lett. 2013 13 2324 2331 10.1021/nl3014154 22616659 Kanapathipillai M.  et al. Nano Lett. 2012 12 3213 3217 10.1021/nl301206p 22554317 Zhao G. Rodriguez B. L. Molecular targeting of liposomal nanoparticles to tumor microenvironment Int. J. Nanomed. 2013 8 61 71 10.2147/ijn.S37859 PMC3534304 23293520 Hickey B. E. Lehman M. Partial breast irradiation versus Cochrane Database Syst. Rev. 2021 8 CD007077 10.1002/14651858.CD007077.pub4 34459500 PMC8406917 Wason M. S. Zhao J. Cerium oxide nanoparticles: potential applications for cancer and other diseases Am. J. Transl. Res. 2013 5 126 131 23573358 PMC3612509 Saranya J.  et al. Biomedicines 2023 11 531 36831067 10.3390/biomedicines11020531 PMC9952927 Sadidi H.  et al. Molecules 2020 25 4559 33036163 10.3390/molecules25194559 PMC7583868 Lan Y.  et al. Nanomaterials 2021 11 1168 33946983 10.3390/nano11051168 PMC8145243 Swartz S. L. Catalysis by ceria and related materials, ed. A. Trovarelli, Catalytic Science Series, vol. 2, Imperial College Press, London, 2002 J. Am. Chem. Soc. 2002 124 12923 12924 10.1021/ja025256e Javad Farhangi M. Es-Haghi A. Taghavizadeh Yazdi M. E. Rahdar A. Baino F. MOF-Mediated Synthesis of CuO/CeO(2) Composite Nanoparticles: Characterization and Estimation of the Cellular Toxicity against Breast Cancer Cell Line (MCF-7) J. Funct. Biomater. 2021 12 53 10.3390/jfb12040053 34698230 PMC8544372 Colon J.  et al. Nanomedicine 2010 6 698 705 10.1016/j.nano.2010.01.010 20172051 Tang J. L. Y. Moonshi S. S. Ta H. T. Nanoceria: an innovative strategy for cancer treatment Cell. Mol. Life Sci. 2023 80 46 10.1007/s00018-023-04694-y 36656411 PMC9851121 An X.  et al. Cell Death Dis. 2024 15 556 10.1038/s41419-024-06939-5 39090114 PMC11294602 Choi H.  et al. Neoplasia 2025 61 101136 10.1016/j.neo.2025.101136 39938153 PMC11869985 Bibb E.  et al. Biology 2021 10 1148 10.3390/biology10111148 34827141 PMC8614948 Swain S. M. Shastry M. Hamilton E. Targeting HER2-positive breast cancer: advances and future directions Nat. Rev. Drug Discovery 2023 22 101 126 10.1038/s41573-022-00579-0 36344672 PMC9640784 Agostinetto E. Curigliano G. Piccart M. Emerging treatments in HER2-positive advanced breast cancer: keep raising the bar Cell Rep. Med. 2024 5 101575 10.1016/j.xcrm.2024.101575 38759648 PMC11228398 Chen P.  et al. Br. J. Cancer 2014 110 2327 2338 10.1038/bjc.2014.155 24667649 PMC4007237 Darguzyte M. Drude N. Lammers T. Kiessling F. Riboflavin-Targeted Drug Delivery Cancers 2020 12 295 32012715 10.3390/cancers12020295 PMC7072493 Karande A. A. Sridhar L. Gopinath K. S. Adiga P. R. Riboflavin carrier protein: a serum and tissue marker for breast carcinoma Int. J. Cancer 2001 95 277 281 10.1002/1097-0215(20010920)95:5&#x0003c;277::aid-ijc1047&#x0003e;3.0.co;2-y 11494224 Thakur K. Tomar S. K. Singh A. K. Mandal S. Arora S. Riboflavin and health: a review of recent human research Crit. Rev. Food Sci. Nutr. 2017 57 3650 3660 10.1080/10408398.2016.1145104 27029320 Witte A. B.  et al. Biomacromolecules 2012 13 507 516 10.1021/bm201566g 22191428 PMC3279152 Majumder R.  et al. In Vitro J. Chem. Inf. Model. 2024 64 5580 5589 10.1021/acs.jcim.4c01104 38982947 Yue J.  et al. J. Mater. Chem. B 2021 9 7972 7978 10.1039/D1TB01291F 34338706 Mekseriwattana W.  et al. Nanoscale Adv. 2022 4 1988 1998 10.1039/D2NA00015F 36133415 PMC9419765 Mekseriwattana W. Thiangtrongjit T. Reamtong O. Wongtrakoongate P. Katewongsa K. P. Proteomic Analysis Reveals Distinct Protein Corona Compositions of Citrate- and Riboflavin-Coated SPIONs ACS Omega 2022 7 37589 37599 10.1021/acsomega.2c04440 36312366 PMC9609060 Mekseriwattana W.  et al. ACS Appl. Nano Mater. 2023 6 13952 13964 10.1021/acsanm.3c01767 Nuchpun S.  et al. ACS Appl. Bio Mater. 2025 8 6088 6099 10.1021/acsabm.5c00649 PMC12284854 40574272 Mekseriwattana W.  et al. co Photochem. Photobiol. 2021 97 1548 1557 10.1111/php.13464 34109623 Thakur N.  et al. Inorg. Chem. Commun. 2022 145 109976 10.1016/j.inoche.2022.109976 Orville A. M. Lountos G. T. Finnegan S. Gadda G. Prabhakar R. Crystallographic, spectroscopic, and computational analysis of a flavin C4a-oxygen adduct in choline oxidase Biochemistry 2009 48 720 728 10.1021/bi801918u 19133805 PMC2646362 Culica M. Andreea C.-S. Melinte V. Coseri S. Cellulose Acetate Incorporating Organically Functionalized CeO 2 Materials 2020 13 2955 10.3390/ma13132955 32630331 PMC7372434 Kanchana E. Sampath U. Yern Chee C. Noothalapati H. Chitosan/Gelatin/Nanocellulose-Based System for Ophthalmic Drug Delivery BioNanoScience 2024 15 42 10.1007/s12668-024-01621-8 Jiao Q.  et al. J. Thorac. Dis. 2014 6 1329 1335 25276378 10.3978/j.issn.2072-1439.2014.08.13 PMC4178098 Podo F.  et al. Mol. Oncol. 2010 4 209 229 10.1016/j.molonc.2010.04.006 20537966 PMC5527939 Vinitha P. Arularasu M. V. Vignesh R. A review on green synthesis and applications of CeO 2 Chem. Inorganic Mater. 2025 5 100084 10.1016/j.cinorg.2024.100084 Dowding J. Dosani T. Kumar A. Seal S. Self W. Cerium oxide nanoparticles scavenge nitric oxide radical (NO) Chem. Commun. 2012 48 4896 4898 10.1039/c2cc30485f 22498787 Atlı Şekeroğlu Z. Şekeroğlu V. Aydın B. Kontaş Yedier S. Cerium oxide nanoparticles exert antitumor effects and enhance paclitaxel toxicity and activity against breast cancer cells J. Biomed. Mater. Res., Part B 2023 111 579 589 10.1002/jbm.b.35175 36221929 Insińska-Rak M. Sikorski M. Wolnicka-Glubisz A. Riboflavin and its Derivates as Potential Photosensitizers in the Photodynamic\nTreatment of Skin Cancers Cells 2023 12 2304 10.3390/cells12182304 37759526 PMC10528563 Criado S. García N. A. Vitamin B2-sensitised photooxidation of the ophthalmic drugs Timolol and Pindolol: kinetics and mechanism Redox Rep. 2004 9 291 297 10.1179/135100004225006047 15606983 Frost Z. Bakhit S. Amaefuna C. N. Powers R. V. Ramana K. V. Recent Advances on the Role of B Vitamins in Cancer Prevention and Progression Int. J. Mol. Sci. 2025 26 1967 40076592 10.3390/ijms26051967 PMC11900642 Al-Jamal A. N.  et al. Health Sci. Rev. 2025 14 100218 10.1016/j.hsr.2025.100218 Sivandzade F. Bhalerao A. Cucullo L. Analysis of the Mitochondrial Membrane Potential Using the Cationic JC-1 Dye as a Sensitive Fluorescent Probe Bio-Protoc. 2019 9 1 10.21769/BioProtoc.3128 PMC6343665 30687773 Wang K.  et al. Nat. Commun. 2025 16 4078 10.1038/s41467-025-59255-7 40307217 PMC12044054 Tang N.  et al. via Exp. Ther. Med. 2022 24 608 10.3892/etm.2022.11545 36160891 PMC9468838 Shanti B. Joy Y.-L. Riboflavin metabolism: role in mitochondrial function J. Transl. Genet. Genomics 2020 4 285 306 10.20517/jtgg.2020.34 ",
  "metadata": {
    "Title of this paper": "Riboflavin metabolism: role in mitochondrial function",
    "Journal it was published in:": "Nanoscale Advances",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481217/"
  }
}